Physician
Greenbrier VMC LLC
Greenbrier VMC LLC was paid $16.33M by Medicaid between Jan 2018 and Jul 2023, across 207 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoGREENBRIER VMC LLC
RONCEVERTE, WV 24970
RONCEVERTE, WV 24970
33aNPI1639124142assigned 05/23/2006
33bProvider typeAnesthesiology Physician
28Total paid$16.33M
24GClaims367,015
24DCodes billed207
24AFirst – last monthJan 2018 – Jul 2023
Compared with peers
Next to other Anesthesiology Physician providers in West Virginia
Rank by total paid#2 of 19
Median peer was paid$529K
This provider vs. median31×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 91,253 | $5.39M | |
| 2019 | 66,108 | $4.35M | |
| 2020 | 84,353 | $3.98M | |
| 2021 | 76,573 | $1.59M | |
| 2022 | 41,816 | $951K | |
| 2023 | 6,912 | $67K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 14,900 | 12,726 | $2.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 5,866 | 4,955 | $1.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.8% | 12,664 | 11,381 | $1.11M |
| 41899 | Unlisted procedure, dentoalveolar structures | 4.0% | 762 | 634 | $651K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 25,248 | 19,087 | $447K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 2,433 | 2,076 | $438K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 2.5% | 5,839 | 4,121 | $401K |
| 80053 | Comprehensive metabolic panel | 2.4% | 19,776 | 15,665 | $397K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 2.3% | 8,314 | 6,486 | $378K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 1.8% | 4,060 | 3,346 | $301K |
| J2704 | Injection, propofol, 10 mg | 1.8% | 4,620 | 3,770 | $299K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 2,829 | 2,523 | $276K |
195 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 3,548 | $244K |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 20,750 | $232K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.4% | 2,936 | $226K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 7,758 | $216K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 7,188 | $205K |
| G0378 | Hospital observation service, per hour | 1.2% | 1,980 | $193K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.2% | 9,391 | $189K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 1.1% | 3,136 | $186K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 5,469 | $181K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.1% | 4,389 | $180K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 3,131 | $178K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 875 | $163K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,638 | $160K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,619 | $158K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,820 | $157K |
| 84484 | <1% | 7,053 | $141K | |
| J3490 | Unclassified drugs | <1% | 18,947 | $135K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,898 | $132K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,992 | $131K |
| 81001 | <1% | 7,631 | $119K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,288 | $117K |
| 87040 | <1% | 5,151 | $103K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,062 | $97K |
| 96376 | <1% | 2,375 | $95K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 202 | $95K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,435 | $94K |
| 83690 | <1% | 4,559 | $88K | |
| 81003 | <1% | 6,011 | $83K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 702 | $81K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 802 | $81K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,409 | $79K |
| 83735 | <1% | 5,098 | $77K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,180 | $77K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,726 | $73K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,406 | $71K |
| 80306 | <1% | 2,256 | $71K | |
| 82962 | <1% | 4,806 | $71K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 958 | $68K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,914 | $67K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,175 | $67K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 889 | $65K |
| 88342 | <1% | 1,110 | $64K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 408 | $64K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 674 | $63K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 215 | $62K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,252 | $57K |
| 83605 | <1% | 3,117 | $57K | |
| 81025 | <1% | 1,318 | $54K | |
| 83880 | <1% | 1,442 | $54K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,049 | $53K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,847 | $53K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,101 | $52K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 668 | $48K |
| 88304 | <1% | 723 | $48K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,685 | $46K |
| 84703 | <1% | 2,104 | $46K | |
| 87077 | <1% | 2,538 | $45K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 89 | $44K |
| 74018 | <1% | 642 | $43K | |
| 82803 | <1% | 1,060 | $42K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 459 | $42K |
| 87186 | <1% | 2,416 | $41K | |
| 93017 | <1% | 171 | $41K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,047 | $41K |
| 85610 | <1% | 2,296 | $40K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,180 | $38K |
| 87430 | <1% | 1,373 | $36K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 129 | $36K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 392 | $35K |
| 93971 | <1% | 442 | $35K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 299 | $35K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 91 | $34K |
| 71250 | <1% | 630 | $33K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 592 | $29K |
| 85027 | <1% | 2,009 | $29K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 744 | $28K |
| 85379 | <1% | 1,029 | $27K | |
| 78226 | <1% | 148 | $27K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,774 | $27K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 226 | $26K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 365 | $26K |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 861 | $25K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 958 | $24K |
| 72100 | <1% | 677 | $24K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 60 | $23K |
| 87070 | <1% | 740 | $21K | |
| 73562 | <1% | 581 | $21K | |
| 85730 | <1% | 1,583 | $21K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 951 | $20K |
| 76770 | <1% | 285 | $18K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 147 | $18K |
| 73610 | <1% | 401 | $18K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 706 | $17K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 249 | $17K |
| 36600 | <1% | 826 | $17K | |
| 82550 | <1% | 620 | $16K | |
| 97161 | <1% | 632 | $16K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 238 | $16K |
| 87807 | <1% | 445 | $16K | |
| 73630 | <1% | 420 | $15K | |
| 73030 | <1% | 461 | $13K | |
| 59025 | Fetal non-stress test | <1% | 379 | $13K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 174 | $13K |
| 73130 | <1% | 327 | $13K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 826 | $12K |
| 82150 | <1% | 329 | $12K | |
| 47562 | <1% | 50 | $12K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 86 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 477 | $12K |
| 73110 | <1% | 184 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 254 | $11K |
| 86850 | <1% | 467 | $11K | |
| 86900 | <1% | 583 | $11K | |
| 86901 | <1% | 585 | $11K | |
| 76641 | <1% | 159 | $10K | |
| 84153 | <1% | 191 | $10K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,614 | $9K |
| 80061 | Lipid panel | <1% | 428 | $9K |
| 45384 | <1% | 51 | $9K | |
| 86140 | <1% | 786 | $9K | |
| 94060 | <1% | 125 | $8K | |
| 96367 | <1% | 106 | $7K | |
| 82553 | <1% | 205 | $7K | |
| D2710 | <1% | 17 | $7K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 30 | $7K |
| 70486 | <1% | 99 | $7K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 333 | $6K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 330 | $6K |
| 94729 | <1% | 90 | $5K | |
| 85652 | <1% | 142 | $5K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 144 | $5K |
| 74022 | <1% | 182 | $5K | |
| 94726 | <1% | 76 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 133 | $5K |
| 82140 | <1% | 96 | $5K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 159 | $4K |
| 84702 | <1% | 80 | $4K | |
| 76536 | <1% | 64 | $4K | |
| 74019 | <1% | 96 | $4K | |
| 80143 | <1% | 315 | $4K | |
| 80179 | <1% | 312 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 561 | $4K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 240 | $4K |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 242 | $4K |
| 84100 | <1% | 248 | $3K | |
| 72050 | <1% | 57 | $3K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 116 | $3K |
| 93970 | <1% | 17 | $3K | |
| 93976 | <1% | 13 | $3K | |
| 90715 | <1% | 82 | $3K | |
| 87184 | <1% | 85 | $3K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 99 | $2K |
| 51702 | <1% | 45 | $2K | |
| 12002 | <1% | 14 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 28 | $2K |
| 87046 | <1% | 14 | $2K | |
| 86308 | <1% | 61 | $2K | |
| 80076 | <1% | 67 | $1K | |
| 72141 | <1% | 24 | $1K | |
| 72072 | <1% | 39 | $1K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 84 | $1K |
| 82272 | <1% | 103 | $1K | |
| 73502 | <1% | 25 | $1K | |
| 87045 | <1% | 14 | $1K | |
| 80050 | General health panel | <1% | 39 | $1K |
| 72131 | <1% | 43 | $999.38 | |
| 87081 | <1% | 19 | $884.26 | |
| 77065 | Tomosynthesis, mammo | <1% | 13 | $680.11 |
| 82010 | <1% | 49 | $616.70 | |
| 74230 | <1% | 15 | $501.47 | |
| 92611 | <1% | 15 | $500.95 | |
| 92526 | <1% | 16 | $498.10 | |
| 73221 | <1% | 12 | $479.60 | |
| 95806 | <1% | 12 | $468.50 | |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 15 | $438.39 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | <1% | 15 | $438.39 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 15 | $438.39 |
| 80069 | <1% | 15 | $404.03 | |
| 73080 | <1% | 15 | $352.27 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15 | $267.34 |
| 84439 | <1% | 15 | $265.49 | |
| 82565 | <1% | 30 | $232.36 | |
| 84520 | <1% | 15 | $194.31 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 17 | $143.59 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 29 | $125.95 |
| 94664 | <1% | 50 | $124.22 | |
| 82607 | <1% | 12 | $111.21 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 14 | $105.27 |
| 82746 | <1% | 12 | $77.08 | |
| 82077 | <1% | 458 | $72.88 | |
| 87205 | <1% | 23 | $38.40 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 13 | $28.51 |
| 94760 | <1% | 58 | $19.25 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 12 | $2.24 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13 | $1.24 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.